China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China).

The chimeric mAb against CD20 was approved

Read the full 276 word article

User Sign In